Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile infection

Author： Borody Thomas J   Brandt Lawrence J   Paramsothy Sudarshan   Agrawal Gaurav  

Publisher： Informa Healthcare

ISSN： 1478-7210

Source： Expert Review of Anti-Infective Therapy, Vol.11, Iss.5, 2013-05, pp. : 447-449

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Probiotics and Fecal Microbiota Transplant for Primary and Secondary Prevention of Clostridium difficile Infection

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 11, 2015-11 ,pp. : 1016-1025

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 9, 2015-05 ,pp. : 835-843

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fear of Failure: Engaging Patients in Antimicrobial Stewardship after Fecal Transplantation for Recurrent Clostridium difficile Infection

By  

Infection Control & Hospital Epidemiology, Vol. 38, Iss. 1, 2016-10 ,pp. : 127-129

Cambridge University Press

Access to resources Recommend Favorite

The long‐term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 371-379

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 8, 2015-10 ,pp. : 1030-1030

John Wiley & Sons Inc

Access to resources Recommend Favorite